HCC treatment
Continue their journey for as long as possible with Nexavar® (sorafenib) then Stivarga® (regorafenib)
Over the past decade, first-line Nexavar has established itself as the standard of care for patients with unresectable HCC by offering increased median overall survival (OS) vs. placebo. Stivarga is the only second-line treatment to be recommended by NICE and accepted for use by the SMC for patients with advanced or metastatic HCC who have tolerated and progressed on Nexavar.
Nexavar then Stivarga, in sequence, have the potential to improve outcomes in your HCC patients (vs Nexavar then placebo) and help you to continue what you started.
Discover how you can learn about survival benefit of your patients with HCC while potentially optimising quality of life by clicking on the relevant treatment goal below.
Nexavar is indicated for the treatment of adult patients with HCC while Stivarga is indicated for the treatment of adult patients with HCC who have been previously treated with Nexavar.
Which aspect of treatment are you interested in?
Mechanism of action
Nexavar is a multikinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro
Abbreviations: BRAF: B-Raf proto-oncogene; serine/threonine kinase; CRAF: C-Raf proto oncogene serine/threonine kinase; c-KIT: c-KIT, c-V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; FLT: fms-like tyrosine kinase; PDGFR: platelet-derived growth factor receptor; RET: rearranged during transfection; VEGFR: vascular endothelial growth factor receptor.
PP-NEX-GB-0211 | February 2024
- expand_more
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.
Further information is available on the "contact" tab at www.bayer.co.uk.
Register with BayerPRO
To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.
Prescribing Information (PI) can be found via the links below:
Nexavar (sorafenib)
Stivarga (regorafenib)
Bayer Pro is owned and funded by Bayer plc
PP-PF-ONC-GB-0396 | February 2024